Effect of obeticholic acid on expression of farnesoid X receptor and cytochrome 7A1 in nonalcoholic fatty liver rats

LIN Hao LIANG Da-wei* ZNEG Jian-feng LI Shu-jian WANG Jian-fu LI Fei

doi:10.16098/j.issn.0529-1356.2018.01.008

PDF(644 KB)

Acta Anatomica Sinica ›› 2018, Vol. 49 ›› Issue (1) : 49-55. DOI: 10.16098/j.issn.0529-1356.2018.01.008

Cell and Molecules Biology

Effect of obeticholic acid on expression of farnesoid X receptor and cytochrome 7A1 in nonalcoholic fatty liver rats

LIN Hao¹ LIANG Da-wei ^1* ZNEG Jian-feng² LI Shu-jian³ WANG Jian-fu⁴LI Fei¹

Author information +

History +

Abstract

Objective To investigate the effect of obeticholic acid on protein expression and gene expression of farnesolid X receptor (FXR), cytochrome 7A1 (CYP 7A1) in non-alcohol fatty liver disease (NAFLD) rat and hepatocyteprotective effect. Methods Fifty two SD rats of the non-alcoholic fatty liver model was established by feeding with high-fat diet. The control group, model group,the experimental group(low), the experimental group(middle), the experimental group(high) were set up. After four weeks of administration, the same part of the liver was taken out. The expression of FXR protein was detected by immunohistochemistry method , the mRNA expression of FXR was detected by RT-PCR, the protein CYP7A1 was detected by Western blotting and the mRNA expression of CYP7A1 was detected by RT-PCR. The liver function was assessed by the rat liver index of the concentrations of peripheral blood alanine aminotransferase (ALT), aspartate transaminase(AST) and alkaline phosphatase(ALP), and the observation of liver sections. Results After fed with high-fat diet for 10 weeks, the rats had typical characteristics of NAFLD and the model was established successfully. The expression of FXR protein and FXR mRNA in the model group were significantly lower than that in the control group (P<0.05). There was no significant difference in the expression of FXR protein and FXR mRNA between the experimental group(low) and the experimental group(middle) (P> 0.05). The expression of FXR protein and FXR mRNA in the experimental group(high) was significantly higher than that in model group (P<0.05). The optical density values of model group, the experimental group(low), and the experimental group(middle) were significantly lower than those of control group (P<0.05). The optical density values of the experimental group(high) was significantly higher, and there was no significant difference compared with those of the control group (P>0.05). The CYP7A1 protein and CYP7A1 mRNA expression levels in the model group were significantly higher than those in the control group (P<0.05). Compared with those in the model group, the expression levels of CYP7A1 protein and CYP7A1 mRNA in the experimental group(low) and the experimental group(middle) had no significant difference (P>0.05). The levels of CYP 7A1 protein and CYP 7A1 mRNA in the experimental group(high) were significantly lower than those in the model group (P<0.05). Compared with the control group, the liver index (%) of the model group increased significantly (P<0.05), while the liver index (%) of the experimental group(low) and the experimental group(middle) had no significant difference compared with the model group (P> 0.05). The liver index (%) of the experimental group(high) was significantly lower than that of the model group (P<0.05). Compared with the control group, the concentrations of ALT, AST and ALP in the model group were significantly increased (P<0.05). The levels of ALT, AST and ALP in the experimental group were significantly lower than those in model group (P<0.05), and the concentrations of ALT, AST and ALP gradually decreased with the increase of acyclobacic acid dosage. The liver tissue sections were observed. The result showed that obeticholic acid improved the histopathology of rats in a dose-dependent manner. Conclusion High doses of acyclobacic acid can significantly upregulate the expression of FXR protein and its gene, inhibit the expression of CYP 7A1 protein and its gene, and significantly improve the liver function and pathological status of rats.

Key words

Obeticholic acid / Non-alcoholic fatty liver / Farnesoid X receptor / Cytochrome 7A1 protein / Western blotting / Rat

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIN Hao LIANG Da-wei ZNEG Jian-feng LI Shu-jian WANG Jian-fu LI Fei. Effect of obeticholic acid on expression of farnesoid X receptor and cytochrome 7A1 in nonalcoholic fatty liver rats[J]. Acta Anatomica Sinica. 2018, 49(1): 49-55 https://doi.org/10.16098/j.issn.0529-1356.2018.01.008

References

［1］Sattar N, Forrest E, Preiss D. Non-alcohol fatty liver disease ［J］. BMJ, 2014,349:g4596.

［2］Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China ［J］. J Heaptol, 2009,50(1):204-210.

［3］Ma FCh, Zhang QY, Wang Sh, et al. Animal model of nonalcoholic fatty liver disease: research advances ［J］. Journal of International Phammaceutical Research, 2017, 44(5):409-414. (in Chinese)

马富超, 张泉洋, 王帅, 等. 非酒精性脂肪肝病动物模型研究进展［J］. 国际药学研究杂志, 2017, 44(5): 409-414.

［4］Li Q, Fu JH. Animal model of nonalcoholic fatty liver disease: research advances ［J］. Practical Clinical Journal of Integrate Traditional Chinese and Western Medicine, 2013, 13(3):92-94. (in Chinese)

李强, 傅继华. 非酒精性脂肪肝动物模型研究进展［J］. 实用中西医结合临床, 2013,13(3):92-94.

［5］Zhang HB, Wang Y. Research progress of non-alcoholic fatty liver disease ［J］. Hainan Medical Journal, 2017, 28(10):1651-1653. (in Chinese)

张海博, 王宇. 非酒精性脂肪肝的现代研究进展［J］. 海南医学, 2017, 28(10):1651-1653.

［6］Zhang L, Niu ShM, Ma HJ. The Progress of bile acids and metabolic syndrome ［J］. Medical Recapitulate, 2016, 22(5): 964-967. (in Chinese)

张柳, 牛尚梅, 马慧娟. 胆汁酸与代谢综合征的研究进展［J］. 医学综述, 2016, 22(5):964-967.

［7］Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes ［J］. Diabetes Care, 2012,35(2):389-395.

［8］Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis ［J］. Hepatology, 2013, 57(4):1394-406.

［9］Liu ST, Liao HY. Clinical research progress of obeticcholic acid ［J］. Beijing Medical Journal, 2015, 37(12): 1174-1176. (in Chinse)

刘松涛, 廖慧钰. 奥贝胆酸的临床研究进展［J］. 北京医学, 2015, 37(12): 1174-1176.

［10］Bjursell M, Wedin M, Admyre T, et al. Ageing FXR deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH ［J］. PLoS One, 2013, 8(5):e64721.

［11］Ma Y, Huang Y, Yan L, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance ［J］. Pharm Res, 2013, 30(5):1447-1457.

［12］Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development ［J］. Nat Rev Gastroenterol Hepatol, 2014, 11(1):55-67.

［13］Chen ShQ, Zhang J, Fang QCh. Recent progress of the role of bile acids in regulating glucose, lipid and energy metabolism ［J］. Medical Recapitulate, 2016, 22(5):947-950. (in Chinese)

陈淑芹, 张菁, 方启晨. 胆汁酸对糖脂及能量代谢调节作用的研究进展［J］. 医学综述, 2016, 22(5):947-950.

［14］Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial ［J］. Lancet, 2015, 385(9972):956-965.